Abbott wins generic Biaxin ruling

Share this article:
Abbott Laboratories Friday won an appeals court ruling stopping Andrx Pharmaceuticals from selling generic versions of its antibiotic Biaxin XL until a patent suit is resolved. The US Court of Appeals for the Federal Circuit said a trial judge was correct in finding that Abbott was likely to win a patent-infringement suit against Andrx. The trial judge ordered Andrx not to sell copies of the drug while the lawsuit was pending. Abbott spokesman Jonathon Hamilton told Bloomberg News the company was pleased with the ruling and it “validates the strength of our intellectual property for Biaxin XL.” Biaxin generated $580 million in global sales in the first nine months of 2006.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.